How it works:
Thalidomide inhibits the formation of new blood vessels (anti-angiogenic), suppresses tumour necrosis factor-alpha (TNF-α), and modulates immune responses. These effects make it suitable for cancer-related conditions and inflammatory complications of leprosy.
Recommended for:
Multiple myeloma (in combination therapy)
Erythema nodosum leprosum (ENL)
Off-label use for chronic inflammation and autoimmune diseases under physician guidance
Patients requiring continuous clinical monitoring
Multiple myeloma
Leprosy-associated erythema nodosum
Off-label: other immune and inflammatory conditions (physician decision)
THALIX-50 is taken orally, usually in the evening due to its sedative properties. Dosage is tailored by a physician according to diagnosis, body weight, and combination protocols. Tablets must be swallowed whole with water.
Pregnancy (high teratogenic risk)
Women of childbearing age without reliable contraception
Known allergy to thalidomide
Severe peripheral neuropathy
Children
Lactose intolerance or glucose-galactose malabsorption
Drowsiness, dizziness
Peripheral neuropathy
Constipation, dry skin, rash
Increased risk of thrombosis
Menstrual cycle irregularities
Anaemia, leukopenia
Severe birth defects (if taken during pregnancy)
